Positive Results Announced from Phase III IMscin001 Study Evaluating Subcutaneous Formulation of Tecentriq® with ENHANZE® in Advanced Non-Small Cell Lung Cancer
Subcutaneous formulation with ENHANZE® reduced treatment time to 3-8 minutes compared to 30-60 minutes for standard intravenous infusion